Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
A phase 3 trial of Tremelimumab, Rilvegostomig, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, now recruiting.
Overview
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT06921785 by AstraZeneca, with 1220 participants planned, started 2025-05-06 and due to reach its primary completion in 2030-03-15. Interventions recorded: Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Tremelimumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Shares Rilvegostomig, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Shares Tremelimumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Shares Tremelimumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Tremelimumab, AstraZeneca, Hepatocellular carcinoma.